Why the study?
SGLT2 inhibitors reduce sudden cardiac death and ventricular arrhythmias in cardiovascular outcome trials, but the electrophysiological mechanism remains unclear.
Do SGLT2 inhibitors improve electrocardiographic markers of ventricular repolarization dispersion?
Comparison
SGLT2 inhibitors vs pre-treatment baseline or other treatments/controls
Design
Systematic review and meta-analysis
Key result
SGLT2 inhibitors significantly reduced QTc (MD -4.9 ms) and Tp-e (MD -6.12 ms) without affecting heart rate or conduction intervals, indicating improved ventricular electrical homogeneity.
Authors
Loading...
SGLT2 inhibitors improve ECG repolarization dispersion markers; extends mechanistic insight into reduced sudden death and ventricular arrhythmias from prior trials.
Systematic Review (n=5,022)
Do SGLT2 inhibitors improve electrocardiographic markers of ventricular repolarization dispersion?
Mean Difference: -4.9
SGLT2 inhibitors reduce ECG markers of ventricular repolarization dispersion without affecting heart rate or conduction intervals, providing a potential electrophysiological mechanism for their observed reduction in sudden cardiac death and ventricular arrhythmias.
Karsa et al. (2026) reported a systematic review. SGLT2 inhibitors vs. Pre-treatment baseline and other treatments was evaluated on QTc (MD -4.9). SGLT2 inhibitors significantly reduced QTc (MD -4.9 ms) and Tp-e (MD -6.12 ms) without affecting heart rate or conduction intervals, indicating improved ventricular electrical homogeneity.